Neurol. praxi. 2018;19(5):380-386 | DOI: 10.36290/neu.2018.121

Ocrelizumab – pharmacoloical profile

doc. MUDr. Radomír Taláb, CSc.1, MUDr. Marika Talábová2
1 Neurologická klinika LF UK a FN Plzeň
2 Neurologická klinika LF UK a FN Hradec Králové

Ocrelizumab (Ocrevus) is a humanized monoclonal antibody that was approved by the US Food and Drug Administration (FDA)on 28th March 2017 for the treatment of relapsing remitting multiple sclerosis (RRMS) and primarily progressive multiple sclerosis(PPMS) approved immunomodulatory treatment. European Medicines Agency (EMA) has recommended 10th November 2017OCR for the treatment of adult RRMS patients and early primary progressive MS patients in the European Union (EU) countries.In the Czech Republic, OCR was registered on 8th January 2017. The treatment is focused on mature B lymphocytes, immune cellsexpressing the protein CD20 molecule on their surface. It is believed that these CD20-positive B-lymphocytes are directed againstthe axons and myelin of healthy neurons, initiating a cascade of immune responses that lead to their damage and consequentlyto the disability in MS patients. This new view on MS pathogenesis was supported by evidence from a phase III, OPERA I, OPERAII and ORATORIO clinical trial.

Keywords: ocrelizumab, relapse remitting MS, primary progressive MS, B-lymphocytes, CD20, biological treatment

Published: October 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Taláb R, Talábová M. Ocrelizumab – pharmacoloical profile. Neurol. praxi. 2018;19(5):380-386. doi: 10.36290/neu.2018.121.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Brück W. The pathology of multiple sclerosis is the reset of focal inflamatory demyelination with axonal damage. J Neurol 2005; 252(Suppl. 5): v3-v9. Go to original source...
    2. Hauser SL, Bar-Or A, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DI, Kingelschmitt G, Masterman D, Fontoura P, Belchew S, Chin P, Mairon N, Garren H, Kappos L, for the OPERA I and OPERA II Clinical Investigators. N Engl J Med 2017; 376 (3): 221-234. Go to original source... Go to PubMed...
    3. Havrdova E, Arnold DL,Bar-Or A, Comi G, Hartung HP, Kappos L, Lublin F, Selmaj K, Traboulsee A, Belachew S, Bennett I, Buffels R, Garren H, Han J, Julian L, Napieralski J, Hauser SL, Giovannoni G. No evidence of disease aktivity (NEDA) analysis by epochs in patiens with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a. MSJ-Experimental, Translational and Clinical, January-March 2018: 1-11. Go to original source...
    4. Hawker K, O'Connor P, Freedman MS, Calabresi PA, Antel J, Simon J, Hauser S, Waubant E, Vollmer T, Panitch H, Zhang J, Chin P, Smith CH. Rituximab in patiens with primary progresive multiple sclerosis: results of a randomised double-blind placebo-controled multicenter trial. Ann Neurol 2009; 66: 460-471. Go to original source... Go to PubMed...
    5. Kappos L, Li D, Calabresi PA, O'Connor P, Bar-Or A, Barkhof F, Yin M, Leppert D, Glanzman R, Tinbergen J, Hauser SL. Ocrelizumab in relapsing-remitting multiple sclerosis a phase 2, randomised, placebo-controled, multicentre trial. Lancet 2011; 378: 1779-1787. Go to original source...
    6. Kimgwell E, Bajdik C, Phillips N, Zhu F, Oger J, Hashimoto S, Tremlett H. Cancer risk in multiple sclerosis: findings from British Columbia, Canada. Brain2012; 135: 2873-2879. Go to original source...
    7. Krejsek J. Biologická terapie ocrelizumabem (antiCD20) je překvapivě klinicky účinná u nemocných s roztroušenou sklerózou mozkomíšní. Neurol. praxi 2017; 18(6): 403-407. Go to original source...
    8. Kubala Havrdová E. Ocrelizumab v léčbě roztroušené sklerózy. Neurol. praxi 2017; 18(4): 287-290. Go to original source...
    9. Lehmann-Horn K, Kronsbein HC, Weber MS. Targeting B cells in the treatment of multiple sclerosis: recent advances and remaining challenges. Ther Adv neurol Disord 2013; 6: 161-173. Go to original source... Go to PubMed...
    10. Margulis AV, Andrews EB, Hernandez-Diaz S, Mygyari M, Rivero-Ferrer E, Bader-Weder S, Everhed J, Garas M, Wang Q, Wormser D. Designs of a Multi-Source Post-Marketing Study to Evaluate Pregnancy and Infant Outcomes in Women with Multiple Sclerosis who exposed to Ocrelizumab During, or within 6 Months before, Pregnancy. AAN 2018: P372. Go to original source...
    11. Milo R. Therapeutic strategies targeting B-cells in multiple sclerosis. Autoimmun Rev. 2016; 15(7): 714-718. Go to original source... Go to PubMed...
    12. Motalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belchew S, Garren H, Mairon N, Chin P, Wolinsky JS, for the ORATORIO Clinical Investigators. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med 2017; 376 (3): 209-220. Go to original source... Go to PubMed...
    13. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69: 292-302. Go to original source... Go to PubMed...
    14. Polman CH, Reingold SC, Edan G, Filippi M,Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O'Connor P, Sandberg-Wollheim W, Thopson M, Alan J, Weinsherker BG, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005; 58: 840-846. Go to original source... Go to PubMed...
    15. Sorensen PS, Blinkenberg M. The potencial role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects. Ther Adv Neurol Disord. 2016; 9(1): 44-52. Go to original source... Go to PubMed...
    16. Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald kriteria. Lancet Neurol 2017, December 21, 2017, http://dx.doi.org/10.1016/S1474-4422(17)30470-2. Go to original source...
    17. Winger RC, Zamvil SS. Antibodies in multiple sclerosis oligoclonal bands target debris. Proc Natl Acad Sci U.S.A 2016; 113(28): 7696-7698. Go to original source...
    18. Winkelmann A, Loebermann M, Reisinger EC, Hartung HP, Zettl UK. Disease modifying therapies and infectious risks in multiple sclerosis. Nat Rev Neurol 2016; 12: 217-233. Go to original source...
    19. Wormser D, Engel P, Hahn K, Bader-Weder S, Didden E-M, Evershed J, Garas M, Wang Q, Hellwig K. Design of the Ocrelizumab Pregnancy Registry to Assess Maternal, Fetal and Infant Outcomes in Women with Multiple Sclerosis who were exposed to Ocrelizumab during, or within 6 Months before, Pregnancy. AAN 2018: P367. Go to original source...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.